Vaccines and profit – a test case for stewardship
So… on the day their partners BioNTec announced the success of their vaccine trial, Albert Bourla, the CEO of Pfizer …
Why ESG isn’t enough
The ESG label is now used so frequently that it is in danger of becoming a substitute for thought.
What …